Celsius Therapeutics Funding: $148M Raised, Series B (2022)
Celsius Therapeutics is based in Cambridge. It has raised $148M in total funding. Latest round: Series B.
Celsius Therapeutics funding overview
Celsius Therapeutics is based in Cambridge. Celsius Therapeutics has raised $148M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in March 2022. The round record for Celsius Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include Third Rock Ventures, Casdin Capital, Alexandria Venture Investments, GV, Heritage Provider Network, Amgen Ventures and 5 others. 11 distinct backers are named across the disclosed rounds.
Celsius Therapeutics at a glance
Total raised
$148M
Latest round
Series B
Latest round date
March 2022
Headquarters
Cambridge
Notable investors
Third Rock Ventures, Casdin Capital, Alexandria Venture Investments, GV, Heritage Provider Network, Amgen Ventures, Amplitude Ventures, Catalio Capital
Frequently asked about Celsius Therapeutics funding
How much has Celsius Therapeutics raised?
Celsius Therapeutics has raised $148M in total disclosed funding across the rounds on record.
Who has invested in Celsius Therapeutics?
Third Rock Ventures, Casdin Capital, Alexandria Venture Investments, GV, Heritage Provider Network, Amgen Ventures are named among the investors backing Celsius Therapeutics.
What was the latest Celsius Therapeutics funding round?
The most recent disclosed round is a Series B, announced in March 2022.
Where is Celsius Therapeutics based?
Celsius Therapeutics is based in Cambridge.
When did Celsius Therapeutics last raise?
The last disclosed Celsius Therapeutics round closed in March 2022 at Series B.
Totals shown for Celsius Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Cambridge and the investors behind them below.
